MET and neoplasm: cMET protein over-expression was seen in more than half of small cell lung cancer (SCLC) and patients with cMET phosphorylation in the SCLC tumours have a markedly poor overall survival (132 vs 287 days for those with cMET phosphorylated tumours and non-phosphorylated tumours respectively, p < 0.001) [28].